MILabs, B.V. the Netherlands‐based innovator and manufacturer of pre‐clinical SPECT/PET/CT imaging devices used in biomedical research, today announces the release of the new mini product family ‐ an easy‐to‐use series of benchtop SPECT and PET imagers for small animals that combine simplified workflow, compact dimensions and affordable pricing to bring high‐performance SPECT/PET within everyone’s reach.

Molecular breast imaging, also known as breast-specific gamma imaging (BSGI), was found to be significantly more sensitive compared to mammography. In fact, BSGI found lesions in 4 percent of women who received a clean bill with mammography, according to a meta-analysis published online by the European Journal of Nuclear Medicine and Molecular Imaging.

For patients suspected to have dementia with Lewy bodies (DLB), SPECT brain imaging of the dopamine transporter (DAT) system has been considered a possible means of evaluating classic symptoms of the disease—hallucinations, cognitive fluctuations, dementia and parkinsonism—and disease-specific changes in striatal dopaminergic function, but researchers have found no such positive connection, according to a study published May 1 by the Journal of Nuclear Medicine.

The PET Response Criteria in Solid Tumors (PERCIST) aim to propel PET from the murky realm of qualitative imaging to a quantitative breakdown of response to cancer treatment.

The Society of Nuclear Medicine and Molecular Imaging (SNMMI) heads north June 8 to June 12 to Vancouver for its annual meeting, dubbed as the premiere educational and networking event in molecular imaging and nuclear medicine.

Poor patient outcomes are associated with primary breast cancer that has metastasized to internal mammary lymph nodes. Researchers compared F-18 FDG PET/CT with results of cytopathologic testing from image-guided fine-needle aspiration, revealing a high percentage of proven metastases from positive FDG PET scans, according to a study published in the May issue of the American Journal of Roentgenology.

Genomics research peering into the pathogenesis of adult de novo acute myeloid leukemia (AML) reveals many important relationships in both genomic and exomic mutations, according to a review published May 1 in the New England Journal of Medicine.

Navidea Biopharmaceuticals, Inc. (NYSE MKT:  NAVB), a biopharmaceutical company focused on the development and commercialization of precision diagnostic radiopharmaceuticals, today announced the U.S. launch of Lymphoseek® (technetium Tc 99m tilmanocept) Injection for use in lymphatic mapping procedures that are performed to help in the diagnostic evaluation of potential cancer spread for patients with breast cancer and melanoma.